Condition or disease | Intervention/treatment | Phase |
---|---|---|
Lymphoma Follicular Lymphoma Follicular Lymphoma, Grade 1 Follicular Lymphoma Grade 2 Follicular Lymphoma Grade IIIa Marginal Zone Lymphoma Marginal Zone B Cell Lymphoma | Drug: Umbralisib Drug: Rituximab | Phase 2 |
This research study is a Phase II clinical trial. Phase II clinical trials test the safety and effectiveness of an investigational drug to learn whether the drug works in treating a specific disease. "Investigational" means that the drug is being studied.
The U.S. Food and Drug Administration (FDA) has not approved Umbralisib as a treatment for any disease.
The FDA has approved Rituximab as a treatment option for this disease.
Umbralisib is an investigational drug which blocks a protein called PI3K. PI3K is a protein that plays a role in the way cells grow. In this type of cancer, PI3K is increased and more active than usual. This helps the cancer cells to grow and survive. Early clinical trials have shown that Umbralisib can kill cancer cells in some patients and cause their tumors to shrink.
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 41 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | A Phase 2 Study of Umbralisib and Rituximab as Initial Therapy for Patients With Follicular Lymphoma and Marginal Zone Lymphoma |
Actual Study Start Date : | September 1, 2019 |
Estimated Primary Completion Date : | November 30, 2022 |
Estimated Study Completion Date : | November 30, 2024 |
Arm | Intervention/treatment |
---|---|
Experimental: Umbralisib+Rituximab
|
Drug: Umbralisib
Umbralisib is an investigational drug which blocks a protein called PI3K. PI3K is a protein that plays a role in the way cells grow. In this type of cancer, PI3K is increased and more active than usual. This helps the cancer cells to grow and survive.
Other Name: TGR-1202
Drug: Rituximab Rituximab works by targeting the CD20 antigen on normal and malignant B-cells. Then the body's natural immune defenses are recruited to attack and kill the marked B-cells
Other Name: MabThera
|
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Participants must have adequate organ function as defined below:
Participants must have adequate marrow function as defined below (unless abnormalities are considered related to marrow involvement by lymphoma):
Exclusion Criteria:
Contact: Jacob D. Soumerai, MD | 617-724-4000 | jsoumerai@mgh.harvard.edu |
United States, Massachusetts | |
Massachusetts General Hospital Cancer Center | Recruiting |
Boston, Massachusetts, United States, 02114 | |
Contact: Jacob D. Soumerai, MD 617-724-4000 jsoumerai@mgh.harvard.edu | |
Principal Investigator: Jacob D. Soumerai, MD | |
Beth Israel Deaconness Medical Center | Recruiting |
Boston, Massachusetts, United States, 02215 | |
Contact: Jon Arnason, MD | |
Principal Investigator: Jon Arnason, MD |
Principal Investigator: | Jacob D. Soumerai, MD | Massachusetts General Hospital |
Tracking Information | |||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
First Submitted Date ICMJE | April 15, 2019 | ||||||||||||||
First Posted Date ICMJE | April 18, 2019 | ||||||||||||||
Last Update Posted Date | September 2, 2020 | ||||||||||||||
Actual Study Start Date ICMJE | September 1, 2019 | ||||||||||||||
Estimated Primary Completion Date | November 30, 2022 (Final data collection date for primary outcome measure) | ||||||||||||||
Current Primary Outcome Measures ICMJE |
Complete Response Rate [ Time Frame: 2 years ] The frequency of patients who achieve a complete response
|
||||||||||||||
Original Primary Outcome Measures ICMJE | Same as current | ||||||||||||||
Change History | |||||||||||||||
Current Secondary Outcome Measures ICMJE |
|
||||||||||||||
Original Secondary Outcome Measures ICMJE | Same as current | ||||||||||||||
Current Other Pre-specified Outcome Measures | Not Provided | ||||||||||||||
Original Other Pre-specified Outcome Measures | Not Provided | ||||||||||||||
Descriptive Information | |||||||||||||||
Brief Title ICMJE | Umbralisib and Rituximab as Initial Therapy for Patients With Follicular Lymphoma and Marginal Zone Lymphoma | ||||||||||||||
Official Title ICMJE | A Phase 2 Study of Umbralisib and Rituximab as Initial Therapy for Patients With Follicular Lymphoma and Marginal Zone Lymphoma | ||||||||||||||
Brief Summary | This research is being done to assess Umbralisib and Rituximab as a first line therapy for Follicular Lymphoma or Marginal Zone Lymphoma. | ||||||||||||||
Detailed Description |
This research study is a Phase II clinical trial. Phase II clinical trials test the safety and effectiveness of an investigational drug to learn whether the drug works in treating a specific disease. "Investigational" means that the drug is being studied. The U.S. Food and Drug Administration (FDA) has not approved Umbralisib as a treatment for any disease. The FDA has approved Rituximab as a treatment option for this disease. Umbralisib is an investigational drug which blocks a protein called PI3K. PI3K is a protein that plays a role in the way cells grow. In this type of cancer, PI3K is increased and more active than usual. This helps the cancer cells to grow and survive. Early clinical trials have shown that Umbralisib can kill cancer cells in some patients and cause their tumors to shrink. |
||||||||||||||
Study Type ICMJE | Interventional | ||||||||||||||
Study Phase ICMJE | Phase 2 | ||||||||||||||
Study Design ICMJE | Allocation: N/A Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Treatment |
||||||||||||||
Condition ICMJE |
|
||||||||||||||
Intervention ICMJE |
|
||||||||||||||
Study Arms ICMJE | Experimental: Umbralisib+Rituximab
Interventions:
|
||||||||||||||
Publications * | Not Provided | ||||||||||||||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
|||||||||||||||
Recruitment Information | |||||||||||||||
Recruitment Status ICMJE | Recruiting | ||||||||||||||
Estimated Enrollment ICMJE |
41 | ||||||||||||||
Original Estimated Enrollment ICMJE | Same as current | ||||||||||||||
Estimated Study Completion Date ICMJE | November 30, 2024 | ||||||||||||||
Estimated Primary Completion Date | November 30, 2022 (Final data collection date for primary outcome measure) | ||||||||||||||
Eligibility Criteria ICMJE |
Inclusion Criteria:
Exclusion Criteria:
|
||||||||||||||
Sex/Gender ICMJE |
|
||||||||||||||
Ages ICMJE | 18 Years and older (Adult, Older Adult) | ||||||||||||||
Accepts Healthy Volunteers ICMJE | No | ||||||||||||||
Contacts ICMJE |
|
||||||||||||||
Listed Location Countries ICMJE | United States | ||||||||||||||
Removed Location Countries | |||||||||||||||
Administrative Information | |||||||||||||||
NCT Number ICMJE | NCT03919175 | ||||||||||||||
Other Study ID Numbers ICMJE | 19-011 | ||||||||||||||
Has Data Monitoring Committee | Yes | ||||||||||||||
U.S. FDA-regulated Product |
|
||||||||||||||
IPD Sharing Statement ICMJE |
|
||||||||||||||
Responsible Party | Jacob Soumerai, MD, Massachusetts General Hospital | ||||||||||||||
Study Sponsor ICMJE | Massachusetts General Hospital | ||||||||||||||
Collaborators ICMJE | TG Therapeutics | ||||||||||||||
Investigators ICMJE |
|
||||||||||||||
PRS Account | Massachusetts General Hospital | ||||||||||||||
Verification Date | August 2020 | ||||||||||||||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |